SAM
MRTX

Shell Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Shell Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,331
Closed -$78K – 1327
2023
Q4 		$78K Sell
1,331
-401
-23% -$22.5K ﹤0.01% 1113
2023
Q3 		$75K Sell
1,732
-28
-2% -$1K ﹤0.01% 1140
2023
Q2 		$64K Sell
1,760
-10
-0.6% -$412 ﹤0.01% 1194
2023
Q1 		$66K Sell
1,770
-6
-0.3% -$270 ﹤0.01% 1161
2022
Q4 		$80K Sell
1,776
-359
-17% -$23.2K ﹤0.01% 1212
2022
Q3 		$149K Sell
2,135
-559
-21% -$41.4K 0.01% 1115
2022
Q2 		$181K Buy
2,694
+5
+0.2% +$318 0.01% 1144
2022
Q1 		$221K Sell
2,689
-398
-13% -$40.7K 0.01% 1144
2021
Q4 		$453K Buy
3,087
+22
+0.7% +$3.42K 0.01% 943
2021
Q3 		$542K Sell
3,065
-140
-4% -$22.5K 0.01% 836
2021
Q2 		$518K Buy
+3,205
New +$515K 0.01% 899
2021
Q1 		– Sell
-1,463
Closed -$321K – 1502
2020
Q4 		$321K Hold
1,463
– – 0.01% 977
2020
Q3 		$243K Hold
1,463
– – 0.01% 981
2020
Q2 		$167K Buy
+1,463
New +$142K ﹤0.01% 1060

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Shell Asset Management's MRTX Position: Q1 2024 in Review

Shell Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,331 shares — an estimated $78K sold.

Shell Asset Management first reported a position in MRTX in Q2 2020 and held it in 14 quarters. The position peaked at $542K in Q3 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Shell Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Shell Asset Management sold 1,331 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $78K.
  • Shell Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 14 quarters.
  • Shell Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $542K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Shell Asset Management's 13F filing for Q1 2024, filed 14 May 2024.